Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Significant Growth in Short Interest

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,310,000 shares, an increase of 22.4% from the March 15th total of 1,070,000 shares. Based on an average daily volume of 115,000 shares, the short-interest ratio is presently 11.4 days. Currently, 16.7% of the company’s stock are short sold.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Adage Capital Partners GP L.L.C. increased its stake in shares of Karyopharm Therapeutics by 46.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock valued at $4,274,000 after acquiring an additional 2,000,000 shares during the period. Jane Street Group LLC boosted its position in shares of Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after purchasing an additional 543,556 shares during the period. Marshall Wace LLP raised its holdings in shares of Karyopharm Therapeutics by 15.3% during the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after acquiring an additional 319,187 shares during the period. Shay Capital LLC acquired a new stake in Karyopharm Therapeutics during the 4th quarter valued at $116,000. Finally, Opti Capital Management LP acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth about $85,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on KPTI. HC Wainwright boosted their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Robert W. Baird reduced their price target on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $57.50.

Karyopharm Therapeutics Stock Up 9.1 %

Shares of NASDAQ:KPTI traded up $0.45 during trading on Monday, reaching $5.40. The stock had a trading volume of 81,398 shares, compared to its average volume of 81,822. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $18.00. The stock has a market cap of $46.28 million, a P/E ratio of -5.29 and a beta of 0.58. The business has a fifty day moving average price of $6.24 and a 200-day moving average price of $9.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. As a group, equities analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).